Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cypros bolsters its low cash burn strategy

Cypros bolsters its low cash burn strategy Although a number of biotech companies have brought multiple products into advanced clinical trials, few have accomplished the mission by spending less than Cypros Pharmaceutical Corp.

Since inception in November 1990, the Carlsbad, Calif., company has spent $7.5 million while moving its two small molecule drugs into five Phase II trials.

The 22-person company is developing CPC-111 and CPC-211 to treat disorders related to low blood flow. CPC-111 is in three Phase II trials to

Read the full 887 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE